In wake of un­ex­pect­ed pa­tient deaths, Macro­Gen­ics clos­es down PhII can­cer tri­al

Macro­Gen­ics is abrupt­ly shut­ting down a Phase II tri­al of its lead ex­per­i­men­tal drug af­ter sev­en pa­tients died in the tri­al.

All 62 pa­tients en­rolled …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.